5 Dividend Stocks to Buy for Steady Income

4. AbbVie Inc. (NYSE:ABBV)

Dividend Yield as of March 19: 3.37%

On March 17, Alloy Therapeutics announced an agreement with AbbVie Inc. (NYSE:ABBV) to develop a new antibody platform. The goal is to discover potent and specific antibodies for targets that current technologies struggle to address. Under the multi-year deal, Alloy will receive an upfront payment, along with an additional payment tied to delivering the platform to AbbVie.

The agreement gives AbbVie access to this antibody discovery platform as part of its broader research efforts. It fits into the company’s ongoing push to expand its pipeline with more targeted therapies. Alloy’s ATX-Gx platform has become widely adopted for fully humanized transgenic mice. It is now used by more than 200 partners across therapeutic discovery programs.

The company continues to reinvest its revenue into research and development. It has expanded its platform over time, adding new strains and tools to keep up with changing demands in antibody discovery. That steady build-out has helped it stay relevant as drug development becomes more complex.

AbbVie Inc. (NYSE:ABBV) focuses on discovering, developing, manufacturing, and selling medicines across areas such as immunology, oncology, aesthetics, neuroscience, and eye care.